Kornimate/medical-research-clean huggingface dataset:
a screening study to assess the cognition status in healthy volunteers

Conditions: Healthy Volunteer

Summary: this multi-center screening study will conduct a cognition assessment to collect reference data for comparison to patients with depression in healthy volunteers. data will be collected for 6 weeks.


Eligibility criteria:
inclusion criteria: * healthy volunteers, 18 to 65 years of age, inclusive * healthy volunteers with a stable chronic disease that is not associated with cognitive deficits (e.g. asthma) and does not require any treatment known to affect cognition have to be discussed with the medical monitor before enrollment * a body mass index between 18 to 30 kg/m2 inclusive * able to participate and willing to give written informed consent and to comply with the study restrictions * at least second generation resident in the country of origin exclusion criteria: * current or past history of a psychiatric disorder * family history of psychiatric disorders * suspicion or evidence of regular consumption of drugs of abuse or a positive drug test at the screening visit * acute or chronic disorder which is not stable or may affect cognition or needs treatment affecting cognition * change of smoking behavior or smoking cessation therapy within 30 days before screening visit * positive result on hepatitis b, hepatitis c, or human immunodeficiency virus (hiv) 1 and 2 * systolic blood pressure greater than 140 or less than 90 mm hg, and diastolic blood pressure greater than 100 or less than 50 mm hg * resting pulse rate greater than 100 or less than 45 beats per minute * clinically significant abnormalities in laboratory test results or in ecg assessment at screening visit * participation in an investigational drug study within 1 month prior to baseline
plasma molecular profiling in alk inhibitor resistant nsclc

Conditions: Non-small Cell Lung Cancer; ALK-Positive Lung Cancer

Summary: the investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection. this study will provide a better understanding of alk resistance in the treatment of asian lung cancers and allow for improved clinical outcomes by 'matching' the secondary mutations to an alk inhibitor which would allow for the greatest coverage ultimately leading to lasting duration of response.


Eligibility criteria:
inclusion criteria: * patients with advanced alk fusion oncogene positive lung adenocarcinoma that have progressed after 1-2 alk inhibitors, with at least one prior line of 2nd generation alki (i.e. ceritinib, alectinib, brigatinib or ensartinib) * the availability of sufficient plasma * age ≥ 21 years * who performance status ≤ 2 * life expectancy of ≥ 21 weeks * patients should have adequate organ function for potential consideration into clinical trials (routine blood tests are valid within 14 days before enrollment): 1. adequate bone marrow function as shown by: anc ≥ 1.0x10\^9/l, platelets ≥ 75x10\^9/l, hb ≥ 7.5 g/dl 2. alanine aminotransferase (alt) and aspirate aminotransferase (ast) normal range (or ≤ 3.0xuln if liver metastases are present) * willing to provide signed informed consent * patients whom do not fulfill the above criteria may be discussed on a case-by-case basis within the study team, for potential enrolment exclusion criteria: * received more than 2 prior alk inhibitors (alki) * symptomatic or uncontrolled brain metastases requiring concurrent treatment inclusive but not limited to surgery and radiation. stable/ tailing doses of corticosteroids is permitted

Keywords: alk inhibitor (alki) nsclc anaplastic lymphoma kinase (alk) fusion oncogene nsclc guardant360 assay next-generation sequencing (ngs) dna sequencing test cell-free circulating tumor dna (ctdna) plasma profiling blood-based assay mutational testing 74 genetic alterations (point mutations, copy number variants, fusions, insertions, deletions) alk resistance mutations
effects of consuming artificial sweeteners and sugar on cerebral and physiological responses

Conditions: Normal Subjects

Summary: this study aims at investigating the acute influence of artificially sweetened beverages consumption (as compared with sugar-sweetened beverages and water consumption) on brain responses to the viewing of food images, on physiological responses (gut-derived hormones and lipid metabolites) and on the food intake behavior.

this study is made on a randomized controlled crossover design including three conditions (water, sugar, artificial sweeteners). measurements will be performed in fasting and fed conditions. the test-meal will comprise either an artificially or sugar-sweetened beverage or water (control). the spatio-temporal brain dynamics to the viewing of food pictures will be assessed by means of electroencephalography (eeg) recordings and electrical neuroimaging analyses. venous blood and urine will be collected. blood pressure, cardiac frequency and bio-impedance measurements will be performed. food intake behavior will be assessed by means of questionnaires and a free-choice buffet. each tested condition (water, sugar, artificial sweeteners) will be preceded by a run-in period during which the participants' diet will be controlled (2-day isoenergetic diet).

Eligibility criteria:
inclusion criteria: * healthy * caucasian * right-handed * weak to normal physical activity (\< 3hours per week) * normal-weight (19\<bmi\<25 kg/m2) * regular consumption of sugar-sweetened beverages (\>33cl per week) exclusion criteria: * consumption of artificially sweetened beverages exceeding 33cl per week * diabetes * cardiovascular, kidney, hepatic and/or psychological disorders * blood pressure at rest \> 140/90mmhg * body weight \< 50kg * hemoglobin \< 13.5g/dl * ferritin \< 50microg/l * drug consumption * alcohol consumption (\>10g/day) * smoking * any particular diet (e.g. vegetarianism), food allergy and/or intolerance * body weight gain or loss of \>3kg during the last 3 months

Keywords: sweeteners sugar eeg food viewing food intake
oral low doses tolerance induction study for peanuts

Conditions: Peanut Allergy

Summary: several protocols have been proposed in scientifis literature, for oral tolerance induction (oit) protocols for peanuts. a meta-analysis showed that the data in the literature are rather in favor of the exclusion of peanuts, and that oit doesn't allow to expect significant levels of peanut protein consumed by the patient, and is associated with an increased risk of anaphylaxis and epinephrine use. also, in most published protocols, patients with a history of anaphylactic shock, severe asthma, or multiple history of anaphylaxis are excluded. to date, no protocol has been validated for this type of treatment, and each center follows locally validated schemes. in our unit, the investigators use an oit protocol that starts at low doses (first dose at 2.68 mg peanut protein) and doses increase is scheduled every 4 to 12 weeks (instead of every 2 weeks). the investigators do not exclude patients with asthma or those with a history of peanut anaphylaxis (grade 2 or 3). the investigators have noted that our protocol is associated with a good safety profile and good efficacy, probably due to the fact that the investigators start at low doses and increase the dose with a prolonged delay, compared to previously published protocols. for this reason, the investigators decided to evaluate the results the investigators obtained in our patients and to better analyze the efficacy and safety profile of our protocol.


Eligibility criteria:
inclusion criteria: * patients evaluated at the montpellier university hospital, allergy unit ; * patients aged 5 years or older; * patients with a history of immediate reaction after consuming peanuts * and a positive peanut prick test; * and peanut positive specific serum ige (immunocap®); * and a positive oral peanut challenge test or a clinical history of anaphylaxis and peanut-specific ige\> 100 kua / l (immunocap®); * patients who started peanut oit between september 2018 and january 2021. exclusion criteria: * patients in exclusion period determined by a previous study; * patients under legal protection, under guardianship or under curatorship; * possible poor therapeutic compliance to the oit protocol; * active malignant neoplasia or autoimmune disease; * active eosinophilic esophagitis or other gastrointestinal eosinophilic disorders; * severe active eczema; * pregnancy ; * cardiovascular disease and use of beta blockers and / or ace inhibitors; * chronic urticaria; * mastocytosis.

Keywords: food allergy peanuts oral immunotherapy efficacy safety peanut ige mediated allergy
adbelimumab combined with chemotherapy and apatinib in patients with resectable esophageal squamous cell carcinoma

Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Treatment

Summary: esophageal cancer is a prevalent digestive tract tumor, with around 400,000 new cases and 300,000 deaths globally each year. in the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma (escc) patients was not significantly decreased. for patients with locally advanced esophageal cancer, direct surgery is not effective. it is difficult to achieve radical resection by surgery merely, and even if many patients receive surgery, they may eventually have tumor recurrence and poor survival rate. therefore, it is necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and improve the postoperative survival rate of patients. according to the reports, the expression of pd-l1 in esophageal cancer was about 41.4%. therefore, pd-1/ pd-l1 immunocheckpoint inhibitor may become a new method for the treatment of escc. preliminary clinical results showed that immunotherapy combined with chemoradiotherapy provided a synergies antitumor effect. the results of the phase 1b trial evaluating adbelimumab monotherapy as a neoadjuvant treatment for locally advanced resectable escc demonstrated that patients receiving two cycles of neoadjuvant sequential surgery exhibited favorable safety profiles, with no adverse reactions of grade 3 or higher. the trial reported a major pathological response (mpr) rate of 24%, a pathological complete response (pcr) rate of 8%, a 2-year overall survival (os) rate of 92%, and a 2-year recurrence-free survival (rfs) rate of 100%. the effectiveness of combining adbelizumab with chemotherapy and targeted therapy for locally advanced esophageal cancer is uncertain. this study aims to assess the efficacy and safety of using adbelizumab with chemotherapy and apatinib as neoadjuvant therapy for resectable escc.


Eligibility criteria:
inclusion criteria: 1. signed informed consent. 2. patients age 18 to 75 years old. 3. primary resectable, histologically confirmed esophageal squamous cell cancer. 4. esophageal squamous cell carcinoma the clinical stage was ii-iva (according to ajcc tnm stage, 8th edition). 5. ecog ps 0-1. 6. no distant metastasis, the diseases could be resectable assessed by thoracic oncologist. exclusion criteria: 1. with significant cardiovascular disease. 2. current treatment with anti-viral therapy or hbv. 3. female patients who are pregnant or lactating. 4. history of malignancy within 5 years prior to screening. 5. active or history of autoimmune disease or immune deficiency. 6. signs of distant metastases.

Keywords: adbelimumab chemotherapy apatinib esophageal squamous cell carcinoma neoadjuvant treatment
uv sensor in patients with actinic keratosis

Conditions: Keratosis, Actinic

Summary: to validate the use of ultraviolet (uv) radiation sensor in patients with actinic keratosis, to identify barriers to its use in prospective longitudinal studies.

to prevent both acute and chronic damage from exposure to uv a and uv b radiation. personal uv exposure can be assessed by portable sensors. having an accurate awareness of one's own behavior (assessed by the accuracy of the uv sensor), can motivate and engage with skin protection.

Eligibility criteria:
inclusion criteria: \>=65 years presenting actinic keratosis on scalp and/or face exclusion criteria: patients who, due to health problems or lifestyle habits, do not expose themselves regularly to uv radiation (outdoor) for at least one hour a day.
effects of interdisciplinary treatment on sickness absence in patients with chronic pain

Conditions: Chronic Pain

Summary: chronic pain is a globally prevalent condition that causes enormous social costs; largely due to sickness absence. a common intervention for patients with chronic pain problems is interdisciplinary treatment (idt), which consists of a combination of physical exercise, cognitive behavioural therapy and work training coordinated in an interdisciplinary team. based on data from swedish national registers, this study evaluates the effects of idt on sickness absence.

this is a completely register-based observational cohort study. the study population is defined from the swedish quality registry for pain rehabilitation (sqrp), which routinely aggregates data from specialist idt pain management clinics across sweden. sqrp contains information on the exposure/intervention: whether a patient that visited a sqrp-affiliated clinic was allocated to an idt program (test) or not (control); t0 defined as the day of the idt assessment. microdata from sqrp is linked to other swedish registers via the unique personal identification number held by all swedish residents. outcome data is obtained from the swedish social insurance agency. registers managed by the national board of health and welfare include data on dispensed prescription pharmaceuticals and specialist health care. markov multistate survival-based methods will be used to compare the sickness absence between groups. specifically, length of stay per sickness absence state (no sickness absence, sick leave, and disability pension) will be compared over five years from t0. both crude and adjusted estimates will be presented. adjustment will be made based on our hypothesis about causal relationships and include: history of sickness absence, sociodemographics (age, sex, sociodemographic status), patient disability (emotional distress, everyday interference, and confidence in future improvement), and governmental policy (idt assessment year and geographical region of idt clinic).

Eligibility criteria:
inclusion criteria: * idt startyear: 2009-2016 * age 18-60 yeras * pain duration of minimum 90 days exclusion criteria: * cancer in the previous 5 years * an idt assessment in the previous 2 years * full or partial disability pension in the year preceding the idt assessment
study of high flow nasal cannula oxygen for bronchoscopy with bronchoalveolar lavage in icu patients

Conditions: Respiratory Insufficiency

Summary: bronchoscopy with bronchoalveolar lavage (bal) is at risk for worsening hypoxemia in patients with acute respiratory failure (arf). high-flow nasal cannula oxygen (hfnc) improves hypoxemia in arf patients . we investigated its efficacy and tolerance in intensive care unit patients admitted for arf requiring bal.

prospective, observational, multicenter study in arf patients (minimal pulse oximetry -spo2- of 92% with an minimal oxygen flow of 6 l/min , respiratory rate \> 25/min (20/min if use of accessory respiratory muscles) with a compatible etiology. primary outcome measure is increase in ventilatory support (non-invasive positive pressure ventilation (nppv) or endotracheal intubation (eti)) within the first 24h following bal.

Eligibility criteria:
inclusion criteria: * presence of acute respiratory failure: defined as respiratory rate greater than 25/min, (or greater than 20/min if use of accessory respiratory muscles was present), in patients requiring oxygen greater than or equal to 6 l/min to obtain a pulse oximetry greater than 92% * need for bronchoalveolar lavage (decision to perform bal was left at the physician's discretion) exclusion criteria: * at least one contraindication to the bronchoscopy with bal: acute coronary syndrome within 6 weeks; neurologic failure; thrombocytopenia less than 30 000/mm3; respiratory acidosis with a ph lower than 7.30 or hypercapnia higher than 60 mmhg; pneumothorax undrained.
effectiveness inspirational muscle training

Conditions: Respiratory Insufficiency

Summary: the long stay in mechanical ventilation can induce several complications, among them respiratory muscle weakness, this has been related to the duration of mechanical ventilation, delay and failure to wean, resulting in longer hospitalization, which reflects in greater care increase in hospital costs. therefore, of this research will be to compare the effectiveness of early inspiratory muscle training (imt) versus non-imt in patients undergoing mechanical ventilation to improve the outcome of mechanical ventilation weaning time.

the study will consist of a randomized controlled clinical trial conducted at the intensive care unit of the university hospital of univasf. will be included individuals of both sexes, aged 18 years or older, who are on invasive mechanical ventilation and who obtain the free and informed consent form, signed by the responsible family member. subjects will be randomized into two groups (training and control). the inspiratory (mip), expiratory (mep) and peak expiratory flow pressures will be evaluated. the training group will perform respiratory muscle training, using the powerbreath equipment, with initial loading of 40% of mip, 7 days a week, 2 times a day. morbidities that have repercussions on diaphragmatic contraction and end-stage disease will be used as exclusion criteria. the sample data will be analyzed through the spss 22.0 program. the significance level of the study will be set at 5% (p \<0.05).

Eligibility criteria:
inclusion criteria: * invasive mechanical ventilation * patients hemodynamically stable * without use of vasoactive drugs exclusion criteria: * spindle trauma * neuromuscular diseases * end-stage disease * pneumothorax * rib fracture * diaphragmatic injury * postoperative pulmonary surgeries * abdominal disease * morbidities that have repercussions on diaphragmatic contraction * mechanical ventilation with fio2 \> 60% and peep \> 10 cm h2o

Keywords: breathing exercises respiratory muscles respiration artificial weaning
validation of the accuracy of a novel poct dry blood gas analyzer in acute care settings

Conditions: Respiratory Failure; Acid-Base Balance Disorder; Sepsis; Shock; Acute Respiratory Distress Syndrome (ARDS)

Summary: the goal of this observational study is to validate the performance of the novel poct dry blood gas analyzer eg-i30, against the currently widely used traditional wet blood gas analyzer, radiometer abl90, in acute care settings. the main questions it aims to answer are: 1. how consistent are the results between eg-i30 and abl90 in acute care settings, including outliers, correlation, linearity, and bias? 2. whether eg-i30 can be considered a suitable alternative to abl90 in acute care settings. participants will be patients in the emergency department who will undergo simultaneous testing with eg-i30 and abl90 during their emergency care to assess the performance of eg-i30.

this observational study aims to compare the performance of two blood gas analyzers, the eg-i30 dry blood gas analyzer and the abl90 wet blood gas analyzer, in an emergency department (ed) or emergency intensive care unit (icu) setting. the study will evaluate the consistency, correlation, and bias between the two analyzers for various blood gas and biochemical parameters, such as potential of hydrogen (ph), partial pressure of oxygen (pao2), partial pressure of carbon dioxide (paco2), sodium (na+), potassium (k+), chloride (cl-), ionized calcium (ica2+), lactate (lac), glucose (glu), and hematocrit (hct). the study design is observational, with no intervention or treatment assigned to the participants. the comparison will be made using residual blood samples collected as part of routine care, following standard clinical procedures.

Eligibility criteria:
inclusion criteria: * patients who are scheduled to undergo arterial blood gas analysis in the emergency department (ed) or emergency intensive care unit (eicu). exclusion criteria: * patients with a confirmed history of infectious diseases such as hepatitis b, syphilis, hiv/aids, etc. * patients whose residual blood samples are not tested within the specified time frame after collection. * other patients deemed ineligible by the investigator (e.g., samples with contamination or other factors affecting sample quality).

Keywords: blood gas analysis accuracy eg-i30 eaglenos
evaluation of coagulation testing in patients undergoing cardiac surgery

Conditions: Congenital Heart Disease

Summary: neonates, children with single ventricle congenital heart disease, and those undergoing multiple complex cardiac surgeries are at high risk of increased perioperative blood loss, and blood product transfusions. in addition, some of these patients will present an increased risk of postoperative thromboembolic complications. for a long time, bleeding management has been based on the empiric administration of different blood products (e.g. platelet concentrates, cryoprecipitates, and/or activated factor vii), topical hemostatic agents, and surgical manipulation. recently, the use of viscoelastic tests (e.g. thromboelastography (teg) or thromboelastometry (rotem)) increased, and allowed a better assessment of perioperative coagulopathy, and a more 'rational' treatment of bleeding. while teg and rotem record the viscoelastic properties of whole blood by measuring mechanical impedance and related changes during clot formation, t2mr, a miniaturized, magnetic resonance-based diagnostic platform, measures how water molecules react in the presence of magnetic fields to evaluate a broad range of hemostasis measurements. in this study, we will prospectively collect demographic data, surgical characteristics, the amount of perioperative bleeding and blood product transfusion, results of laboratory assays, and postoperative outcomes (30-day follow-up or until discharge), with the aim to assess our current practice, and develop an algorithm-based approach for the administration of targeted blood product and pro-coagulant therapies. our goals are: the reduction of blood product utilization, the reduction of the incidence of massive bleeding and postoperative thrombosis.


Eligibility criteria:
inclusion criteria: * neonates and infant patients (0 -12 months of age) undergoing complex cardiac surgical procedures * cardiac surgery patient \> 12 months of age who has previously undergone 2 or more sternotomies exclusion criteria: * child in a moribund condition (american society of anesthesiology (asa 5) * children with a hematological and/or oncological disease * jehovah witnesses * if the child is only undergoing a patent ductus arteriosus (pda) ligation or other procedures not considered at risk for thrombosis and/or bleeding or they do not provide consent for enrollment (e.g. ventricular septal defect repair)

Keywords: congenital heart disease point-of-care coagulation monitoring